茶多酚抑制肺鳞癌细胞裸鼠移植瘤的实验研究

目的:探索茶多酚对肺鳞癌细胞的抑制效应及相关机制.方法:以肺鳞癌PC10为研究对象,进行裸鼠成瘤实验.观察茶多酚对裸鼠成瘤的影响.应用免疫组织化学方法检测细胞凋亡相关Bc12和Caspas3和增殖相关蛋白PCNA的表达,应用TUNNEL法检测细胞凋亡.结果:茶多酚可抑制裸鼠移植瘤的生长.茶多酚可促进促凋亡蛋白caspase3表达并抑制抑凋亡蛋白Bc12表达,并抑制增殖细胞核抗原的表达.TUNNEL实验结果提示茶多酚可促进PC10细胞凋亡.结论:茶多酚可抑制肺鳞癌移植瘤生长,与促进癌细胞凋亡和抑制细胞增殖有关.     

茶色素对人肺鳞癌细胞株SK-MES-1 细胞生长及凋亡的影响

目的:探讨茶色素对人肺鳞癌细胞株SK-MES-1细胞生长及凋亡的影响。方法:以超声细胞破碎法提取茶色素并计算得率。常规培养SK-MES-1细胞株,采用噻唑蓝溴化四唑(MTT)比色法观察不同浓度(5、2.5、1.25、0.625、0.3125 mg/m L)茶色素作用24、48 h对SK-MES-1细胞株生长的抑制作用,计算生长抑制率及IC_(50);以流式细胞术(FCM)荧光双染法(Annexin V/PI)观察茶色素对SK-MES-1细胞株凋亡的影响。结果:茶色素提取得率为7.35%。MTT实验结果显示随茶色素浓度增高和培养时间延长,其对细胞的生长抑制率也相应升高,即呈现剂量-时间依赖性,24 h和48 h处理的IC_(50)分别为2.353 mg/m L和1.494 mg/m L。流式细胞术检测作用24 h细胞凋亡,空白对照、0.625 mg/m L和1.25 mg/m L剂量组的SK-MES-1细胞凋亡率分别为7.7%、20.37%和25.25%。结论:茶色素可促进SK-MES-1细胞凋亡并抑制其增殖。     

Survivin基因RNA干扰对肺癌细胞凋亡及增殖的影响

目的:探讨Survivin表达对肺鳞癌细胞的凋亡和增殖的影响.方法:利用siRNA阻抑人肺鳞癌细胞内survivin基因的表达,用RT-PCR和Western Blotting法分析survivin基因mRNA和蛋白的表达,流式细胞术检测细胞凋亡率,细胞集落形成实验检测细胞增殖.结果:(1)Survivin在肺癌细胞中表达.转染Survivin siRNA可在RNA和蛋白水平阻断其表达;(2)转染Survivin siRNA的肺癌细胞凋亡率显著增加;(3)转染Survivin siRNA的肺癌细胞的集落形成率显著降低.结论:阻断Survivin表达可通过增加细胞凋亡率和降低细胞增殖增加肺鳞癌细胞的放疗敏感性.     

野生仙人掌多糖对肺鳞癌细胞SK-MES-1 生长的抑制作用

目的:探讨仙人掌多糖对体外肺鳞癌细胞(SK-MES-1)生长抑制作用。方法:体外培养SK-MES-1细胞,四甲基偶氮唑盐(MTT)法观察野生仙人掌多糖对其生长的抑制,计算最低抑制浓度及抑制率;观察不同浓度多糖对细胞形态的影响;SDS-PAGE凝胶电泳简析不同组别蛋白质表达的差异。结果:野生仙人掌多糖24 h和48 h对肿瘤细胞的最低抑制浓度和抑制率分别为0.0625 mg/ml.34.06%和0.0625 mg/ml 35.37%;不同组间蛋白质表达有差异。结论:野生仙人掌多糖对SK-MES-1肺鳞癌细胞有抑制作用。     

PHP14沉默对肺癌细胞凋亡的影响及其机制

目的:在肺癌细胞中沉默PHP14,并研究其对肺癌细胞凋亡的影响及其可能机制。方法:利用shRNA稳定沉默肺癌细胞株A549中PHP14的表达,并利用Annexin V、PI双染和流式细胞仪检测细胞在正常培养条件下和凋亡诱导条件下的凋亡情况;通过皮下接种裸鼠,探讨PHP14沉默对肺癌细胞体内成瘤的影响,并利用Realtime-PCR和Western blotting检测PHP14沉默后凋亡相关基因的表达情况。结果:成功获得了PHP14稳定沉默的肺癌细胞株,发现PHP14沉默可促进肺癌细胞诱导性凋亡,并抑制肺癌细胞的体内成瘤能力,并且发现PHP14沉默对肺癌细胞凋亡的影响可能是通过抑制Bcl-2表达实现的。结论:PHP14沉默可促进肺癌细胞诱导性凋亡,并可能通过抑制Bcl-2影响肺癌细胞凋亡。     

二甲基胂酸抑制胃癌细胞增殖的研究

目的:探讨二甲基胂酸(DMAA)对SGC7901胃癌细胞增殖的抑制作用及其可能的机制.方法:依次用5,10,15,20,25,30mmol/L二甲基胂酸处理培养的SGC7901胃癌细胞24 hrs,在5 mmol/L和10 mmol/L的浓度下分别处理6,12,18.24,30,36,42,48hrs,用MTT计数法测定DMAA对肿瘤细胞增殖的抑制率,用激光共聚焦显微镜检测细胞形态变化以及用DNA凝胶电泳检测细胞凋亡.结果:DMAA在不同浓度下对肿瘤细胞的抑制作用呈现典型的双曲线,即随着浓度的增加DMAA对胃癌细胞的抑制率不断增加并逐渐趋于稳定;在形态学上DMAA在低浓度下引起胃癌细胞的胞膜出泡、核固缩、染色体断裂和凋亡小体等典型的细胞凋亡的变化,而在高浓度下主要引起细胞坏死;DNA凝胶电泳结果显示,在低浓度DMAA作用下胃癌细胞DNA呈现细胞凋亡的梯状带型,而在高浓度下梯状带型则消失.结论:DMAA抑制胃癌细胞的增殖,其在低浓度时能有效诱导胃癌SGC 7901细胞凋亡,而在高浓度时使胃癌细胞坏死而死亡.     

小鼠正常肺细胞和肺癌细胞之间的力学特性比较研究

该实验通过鬼笔环肽染色技术观察并比较了小鼠正常肺细胞和肺癌细胞的微丝差异,利用荧光抗体染色技术测定了小鼠单个正常肺细胞和肺癌细胞的α-SMA蛋白含量变化,以及利用CTFM法测定了小鼠正常肺细胞和肺癌细胞的牵引力变化。结果发现,小鼠肺细胞癌变后,细胞内微丝骨架发生了变化,影响了细胞的形态;α-SMA蛋白含量明显下降并且变得分散：细胞投影面积显著减少,大约减少27％,细胞牵引力也显著减小,均方根值大约减少49％。这说明细胞骨架、细胞的形态、α-SMA蛋白和细胞牵引力均与细胞的癌变过程密切相关。     

活细胞中丝裂霉素诱导肺腺癌细胞凋亡机理的分析

为了分析丝裂霉素(mitomycin C,MMC)引起的肺腺癌细胞(ASTC-a-1)凋亡,实验通过CCK-8试剂盒检测不同浓度MMC对ASTC-a-1活性的影响,选择10μgS/mL的MMC处理ASTC-a-1.利用Hochest 33258染色观察MMC引起的ASTC-a-1凋亡,发现MMC可引起细胞缩小,核浓缩.为了进一步研究MMC引起凋亡的途径,通过脂质体转染pSCAT3质粒,利用光漂白技术和光谱技术观察Caspase-3是否活化;通过转染Bax和DsRed质粒观察Bax在凋亡过程中的位置变化及与线粒体的关系.结果显示:MMC可以诱导ASTC-a-1细胞内Caspase-3活化,并使Bax向线粒体转移聚集.在活细胞中证实Caspase-3和Bax参与了MMC引起的ASTC-a-1凋亡.     

A549/DDP细胞的抗凋亡特性与其pHi和[Ca2+]i变化相关

以l临床用药剂量(30μmol/L)的顺铂处理敏感的人肺腺癌细胞A549和抗顺铂的A549/DDP细胞,在相同条件下培养.对培养不同时间的两株细胞DNA琼脂糖凝胶电泳分析的结果表明,前者在培养12h后即呈现DNA梯子,而后者在培养48h后却未见凋亡特征.用流式细胞计检测其凋亡峰也获得相似的结果.当测定与凋亡相关的生物化学和生物物理变化时发现对顺铂敏感的A549细胞的线粒体膜电势显著降低,胞内更加酸化且胞内钙离子浓度升高;而抗顺铂药物的A549/DDP细胞的线粒体膜电势和pH值却维持在相对较高的水平,而其胞内钙离子浓度随培养时间的延长下降.这些结果表明,抗顺铂的人肺腺癌A549/DDP细胞的抗凋亡特性与其胞内的相对碱化和较高的线粒体膜电势,以及胞内钙离子浓度的降低相关.这些特性可能参与了A549/DDP的顺铂耐药性的调节.     

血啉甲醚在鼻咽癌细胞中的浓度分布

利用激光诱导荧光方法实验测定了新型光敏剂血啉甲醚（Hematoporphyrin Monomethyl Ether, HMME）在鼻咽癌细胞株CNE中的时间分布和浓度变化规律.实验结果表明,鼻咽癌细胞株CNE的荧光光谱中的两个特征峰615 nm和675 nm证实了鼻咽癌细胞对HMME的选择性特异吸收.HMME在鼻咽癌细胞中的潴留浓度在混合培养后的140分钟达到最大值.当用于培养鼻咽癌细胞的HMME药物浓度低于32 μg/ml时,测量得到的相对荧光光谱强度与HMME浓度呈现出很好的线性关系,通过拟合方程可以间接确定在给定注射剂量条件下鼻咽癌细胞中所潴留HMME的浓度.结果可以为HMME在光动力学诊断与治疗中的临床应用提供理论依据和剂量参考.     

Cytological diagnostic clues in poorly differentiated squamous cell carcinomas of the breast: Streaming arrangement,necrotic background,nucleolar enlargement and cannibalism of cancer cells

Objective

Squamous cell carcinoma (SCC) is a rare histological type of breast cancer. The cytological diagnosis of non‐keratinising, poorly differentiated SCC is often difficult, and distinguishing it from invasive ductal carcinoma or apocrine carcinoma (AC) is especially challenging. We aimed to define the diagnostic cytological features of poorly differentiated SCC of the breast.

Methods

We studied the cytological findings of poorly differentiated SCC (n=10) and compared them to those of IDC (n=15) and AC (n=14). The following six cytological features were evaluated: streaming arrangement, nucleolar enlargement, dense nuclei, cannibalism, atypical keratinocytes and necrotic background.

Results

SCC exhibited significantly higher frequencies of streaming arrangement (70% vs 6.7%, P=.002), nucleolar enlargement (80% vs 27%, P=.02), and necrotic background (80% vs 36%, P=.002) than invasive ductal carcinoma. The detection of two or three of these features yielded a higher sensitivity (80%) and specificity (93%) for the diagnosis of SCC. Streaming arrangement (70% vs 0%, P<.001), cannibalism (60% vs 0%, P=.002), and a necrotic background (80% vs 36%, P=.047) were all significantly more frequent in SCC than in AC. When distinguishing SCC from AC, the presence of two or three of these features yielded a high sensitivity (80%) and specificity (100%).

Conclusions

Cytological features such as a streaming arrangement, a necrotic background, nucleolar enlargement and cannibalism are useful indicators for the diagnosis of SCC of the breast. As such, greater attention should be paid to these morphological features in daily clinical practice.     

The disturbances of the zinc concentration in the blood in selected neoplasms

A study was carried out on 92 patients (58 males and 34 females) aged 42–76 treated for malignant neoplasm of the gastrointestinal tract (54 patients with colorectal carcinoma, 38 with gastric carcinoma). In all patients, the zinc serum concentration was measured and the results obtained were referred to some epidemiological-clinical factors (sex, age, primary cause of cancer, the stage of clinical progression, and histological type). The results showed that the most pronounced hypozincemia occurred in male patients with mucous membrane carcinoma of the stomach.     

KLN205—A murine lung carcinoma cell line

Summary KLN205 cells, a cloned cell line established from the Nettesheim lung carcinoma, grow in various synthetic media such as MEM, Fisher's or Roswell Park Memorial Institute Medium (RPMI) with the addition of 5 to 20% fetal bovine serum (FBS), calf serum (CS) or horse serum (HS). They grow optimally in minimum Eagle's medium plus nonessential amino acids (NEAA) plus 5 to 10% FBS or HS. The cells are transplantable to DBA/2, BDF₁, AKD₂F₁, and BALB/c, but not to C3H/He or ICR mice. The growth curves, plating efficiency, ultrastructural characteristics, modal number of chromosomes and transplantability to mice of various strains are almost the same for early and late passages of cells passaged in vitro. These parameters for 16th and 36th passages were: doubling time, 31 and 33 hr; plating efficiency, 12.4±1.2 and 14.6±2.6%; modal number of chromosomes, 73 and 76; lung colony formation in DBA/2, 50 and 45.9/mouse; and subcutaneous tumor diameter 24.5 and 27.4 mm, respectively. Only the numbers of lung colonies formed in BDF₁ mice were different: 24.4/mouse with 16th passage cells, and 10.2/mouse with 36th passage cells. The results suggest that KLN205 is a relatively stable cultured cell line through 36 passages. As was expected, immunosuppression by higher concentrations of triaminolone acetonide (TA) enhanced lung colony formation in BDF₁ mice. On the other hand, a low concentration of TA inhibited lung colony formation in DBA/2 mice, which was unexpected. These results suggest that KLN205 offers a model for investigations on metastases to lungs as well as chemotherapy for lung carcinoma. This work was supported by the National Cancer Institute of Canada.     

LIPOSOMAL DAUNORUBICIN OVERCOMES DRUG RESISTANCE IN HUMAN BREAST,OVARIAN AND LUNG CARCINOMA CELLS

ABSTRACT

Multi-drug resistance due in part to membrane pumps such as P-glycoprotein (Pgp) is a major clinical problem in human cancers. We tested the ability of liposomally-encapsulated daunorubicin (DR) to overcome resistance to this drug. A widely used breast carcinoma cell line originally selected for resistance in doxorubicin (MCF7ADR) was 4-fold resistant to DR compared to the parent MCF7 cells (IC₅₀ 79 nM vs. 20 nM). Ovarian carcinoma cells (SKOV3) were made resistant by retroviral transduction of MDR1 cDNA and selection in vinblastine. The resulting SKOV3MGP1 cells were 130-fold resistant to DR compared to parent cells (IC₅₀ 5700 nM vs. 44 nM). Small-cell lung carcinoma cells (H69VP) originally selected for resistance to etoposide were 6-fold resistant to DR compared to H69 parent cells (IC₅₀ 180 nM vs. 30 nM). In all three cases, encapsulation of DR in liposomes as Daunoxome (Gilead) did not change the IC₅₀ of parent cells relative to free DR. However, liposomal DR overcame resistance in MCF7ADR breast carcinoma cells (IC₅₀ 20 nM), SKOV3MGP1 ovarian carcinoma cells (IC₅₀ 237 nM) and H69VP small-cell lung carcinoma cells (IC₅₀ 27 nM). Empty liposomes did not affect the IC₅₀ for free DR in the three resistant cell lines, nor did empty liposomes affect the IC₅₀ for other drugs that are part of the multi-drug resistance phenotype (etoposide, vincristine) in lung carcinoma cells. These data indicate the possible value of liposomal DR in overcoming Pgp-mediated drug resistance in human cancer.     

Heparanase expression and localization in different types of human lung cancer

Background

Heparanase is the only known mammalian glycosidase capable of cleaving heparan sulfate chains. The expression of this enzyme has been associated with tumor development because of its ability to degrade extracellular matrix and promote cell invasion.

Methods

We analyzed heparanase expression in lung cancer samples to understand lung tumor progression and malignancy. Of the samples from 37 patients, there were 14 adenocarcinomas, 13 squamous cell carcinomas, 5 large cell carcinomas, and 5 small cell carcinomas. Immunohistochemistry was performed to ascertain the expression and localization of heparanase.

Results

All of the tumor types expressed heparanase, which was predominantly localized within the cytoplasm and nucleus. Significant enzyme expression was also observed in cells within the tumor microenvironment, such as fibroblasts, epithelial cells, and inflammatory cells. Adenocarcinomas exhibited the strongest heparanase staining intensity and the most widespread heparanase distribution. Squamous cell carcinomas, large cell carcinomas, and small cell carcinomas had a similar subcellular distribution of heparanase to adenocarcinomas but the distribution was less widespread. Heparanase expression tended to correlate with tumor node metastasis (TNM) staging in non-small cell lung carcinoma.

Conclusion

In this study, we showed that heparanase was localized to the cytoplasm and nucleus of tumor cells and to cells within the microenvironment in different types of lung cancer. This enzyme exhibited a differential distribution based on the type of lung tumor.General significanceElucidating the heparanase expression patterns in different types of lung cancer increased our understanding of the crucial role of heparanase in lung cancer biology. This article is part of a Special Issue entitled Matrix-mediated cell behaviour and properties.     

Oral squamous cell carcinoma in capuchin monkeys (Cebus apella). Report of two cases.

Two neoplasms were observed in two feral male Cebus apella monkeys of approximately 12 and 14 years of age. Histologically, the tumors were well-differentiated squamous cell carcinomas, one affecting the soft and hard palates reaching the nasal cavity and the other involving the oral cavity floor and the inferior maxillar.     

Pin1和Cyclin D1在人类5种常见肿瘤中的表达及其意义

目的研究人类的肽基脯氨酰异构酶(Pin1)在人类几种重要的肿瘤(肺癌、前列腺癌、乳腺癌、宫颈癌和胃癌)中的表达及与细胞周期蛋白CyclinD1的关系,并探讨它们在肿瘤的发病机制、诊断和治疗中的意义。方法随机收集33例正常组织和171例癌组织(包括37例肺癌、35例前列腺癌、31例乳腺癌、36例宫颈癌和32例胃癌)。采取免疫组织化学Envision法显示Pin1和CyclinD1的表达。结果Pin1和CyclinD1在正常组织中不表达或者低表达,而在各种癌组织中有普遍性的高表达,在肺癌组织、前列腺癌组织、乳腺癌组织、胃癌组织和宫颈癌组织中,Pin1的表达率分别为48·7%、65·7%、48·4%、15·6%和69·4%,CyclinD1的表达率分别为56·8%、60·0%、54·8%、40·6%和58·3%。Pin1和CyclinD1在癌组织中的表达明显高于正常组织中的表达(P<0·05)。Pin1和CyclinD1蛋白在肺癌、前列腺癌、乳腺癌和宫颈癌中表达呈显著正相关(P<0·05)。而Pin1和CyclinD1蛋白在胃癌中的表达相关性不显著(P>0·05)。结论Pin1和CyclinD1在多种肿瘤的发生、发展过程中具有重要作用,如肺癌、前列腺癌、乳腺癌、宫颈癌和胃癌,Pin1与细胞周期代谢或调控有关。Pin1在某些肿瘤(如肺癌、前列腺癌等)中可作为肿瘤标记的参考指标。     

Un adénocarcinome mucineux non kystique (carcinome colloïde) du pancréas de découverte fortuite à la TEP-TDM au 18F-FDG : à propos d’un cas

Colloid carcinoma (CC) of the pancreas, also known as mucinous noncystic carcinoma, is a rare histological variant of pancreatic cancer which had been included in the past under the category of ordinary ductal carcinoma, a tumor with a dismal prognosis, or was frequently misdiagnosed as mucinous cystadenocarcinoma. As CC has a better prognosis than pancreatic ductal carcinoma, early detection of CC by 18 FDG PET SCAN is of great value for the therapeutic management of patients. We report the case of a 66-year-old patient who underwent 18 FDG PET SCAN as part of a post-therapy evaluation of a moderately differentiated carcinoma of the stomach treated with surgery and chemotherapy, in whom a hypermetabolic focus of the body of the pancreas was discovered incidentally. The anathomopathological diagnosis was in favor of a low-grade mucinous noncystic carcinoma of the pancreas. Thus, 18 FDG PET SCAN allowed the discovery of an infraradiological CC synchronous with a gastric adenocarcinoma and provided information on its metabolic activity as well as locoregional and distant staging, which are important prognostic markers and which could improve the therapeutic management of the patient.     

HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options

Abstract

Adenocarcinomas of the esophagus and stomach constitute a substantial number of cancer cases worldwide. Most patients in the United States are diagnosed at an advanced or metastatic stage and, therefore, the prognoses have been poor. New treatments are needed to augment standard surgical and medical management. Recent studies have shown that a subset of esophageal and gastric adenocarcinomas overexpress the HER2 protein, similar to the overexpression seen in breast cancer. Because trastuzumab, a monoclonal antibody to the HER2 receptor, has been used with success in primary and HER2 positive metastatic breast cancers, the phase III ToGA trial was designed to assess the impact of trastuzumab in patients with HER2 positive gastric cancers. They have reported an increase in overall survival time for patients treated with chemotherapy and trastuzumab compared to those treated with chemotherapy alone. They have reported an increase in overall survival time for patients treated with chemotherapy and trastuzumab compared to those treated with chemotherapy alone. This means that accurate HER2 testing in gastric and esophageal carcinomas is necessary. While the breast cancer scoring system can be used to determine HER2 status in most cases, modifications are necessary to accommodate the heterogeneity and incomplete membrane staining that are observed more frequently in gastric cancers. An understanding of the scoring modifications is required for proper stratification of gastric cancer patients for treatment.